Stock Analysis

Calculating The Intrinsic Value Of Nexstim Plc (HEL:NXTMH)

HLSE:NXTMH
Source: Shutterstock
Advertisement

Key Insights

  • Using the 2 Stage Free Cash Flow to Equity, Nexstim fair value estimate is €19.04
  • With €15.45 share price, Nexstim appears to be trading close to its estimated fair value
  • Nexstim's peers seem to be trading at a higher discount to fair value based onthe industry average of 28%

In this article we are going to estimate the intrinsic value of Nexstim Plc (HEL:NXTMH) by taking the expected future cash flows and discounting them to their present value. One way to achieve this is by employing the Discounted Cash Flow (DCF) model. Don't get put off by the jargon, the math behind it is actually quite straightforward.

Companies can be valued in a lot of ways, so we would point out that a DCF is not perfect for every situation. If you still have some burning questions about this type of valuation, take a look at the Simply Wall St analysis model.

The Calculation

We use what is known as a 2-stage model, which simply means we have two different periods of growth rates for the company's cash flows. Generally the first stage is higher growth, and the second stage is a lower growth phase. In the first stage we need to estimate the cash flows to the business over the next ten years. Where possible we use analyst estimates, but when these aren't available we extrapolate the previous free cash flow (FCF) from the last estimate or reported value. We assume companies with shrinking free cash flow will slow their rate of shrinkage, and that companies with growing free cash flow will see their growth rate slow, over this period. We do this to reflect that growth tends to slow more in the early years than it does in later years.

A DCF is all about the idea that a dollar in the future is less valuable than a dollar today, so we need to discount the sum of these future cash flows to arrive at a present value estimate:

10-year free cash flow (FCF) forecast

2026202720282029203020312032203320342035
Levered FCF (€, Millions) €4.70m€5.10m€6.10m€6.50m€6.80m€7.05m€7.27m€7.46m€7.64m€7.80m
Growth Rate Estimate SourceAnalyst x1Analyst x1Analyst x1Analyst x1Est @ 4.59%Est @ 3.71%Est @ 3.09%Est @ 2.66%Est @ 2.36%Est @ 2.14%
Present Value (€, Millions) Discounted @ 6.4% €4.4€4.5€5.1€5.1€5.0€4.9€4.7€4.5€4.4€4.2

("Est" = FCF growth rate estimated by Simply Wall St)
Present Value of 10-year Cash Flow (PVCF) = €47m

The second stage is also known as Terminal Value, this is the business's cash flow after the first stage. For a number of reasons a very conservative growth rate is used that cannot exceed that of a country's GDP growth. In this case we have used the 5-year average of the 10-year government bond yield (1.7%) to estimate future growth. In the same way as with the 10-year 'growth' period, we discount future cash flows to today's value, using a cost of equity of 6.4%.

Terminal Value (TV)= FCF2035 × (1 + g) ÷ (r – g) = €7.8m× (1 + 1.7%) ÷ (6.4%– 1.7%) = €167m

Present Value of Terminal Value (PVTV)= TV / (1 + r)10= €167m÷ ( 1 + 6.4%)10= €90m

The total value, or equity value, is then the sum of the present value of the future cash flows, which in this case is €137m. The last step is to then divide the equity value by the number of shares outstanding. Relative to the current share price of €15.5, the company appears about fair value at a 19% discount to where the stock price trades currently. Valuations are imprecise instruments though, rather like a telescope - move a few degrees and end up in a different galaxy. Do keep this in mind.

dcf
HLSE:NXTMH Discounted Cash Flow July 9th 2025

The Assumptions

Now the most important inputs to a discounted cash flow are the discount rate, and of course, the actual cash flows. Part of investing is coming up with your own evaluation of a company's future performance, so try the calculation yourself and check your own assumptions. The DCF also does not consider the possible cyclicality of an industry, or a company's future capital requirements, so it does not give a full picture of a company's potential performance. Given that we are looking at Nexstim as potential shareholders, the cost of equity is used as the discount rate, rather than the cost of capital (or weighted average cost of capital, WACC) which accounts for debt. In this calculation we've used 6.4%, which is based on a levered beta of 0.975. Beta is a measure of a stock's volatility, compared to the market as a whole. We get our beta from the industry average beta of globally comparable companies, with an imposed limit between 0.8 and 2.0, which is a reasonable range for a stable business.

View our latest analysis for Nexstim

Next Steps:

Valuation is only one side of the coin in terms of building your investment thesis, and it is only one of many factors that you need to assess for a company. DCF models are not the be-all and end-all of investment valuation. Preferably you'd apply different cases and assumptions and see how they would impact the company's valuation. For instance, if the terminal value growth rate is adjusted slightly, it can dramatically alter the overall result. For Nexstim, there are three further factors you should explore:

  1. Risks: For instance, we've identified 1 warning sign for Nexstim that you should be aware of.
  2. Future Earnings: How does NXTMH's growth rate compare to its peers and the wider market? Dig deeper into the analyst consensus number for the upcoming years by interacting with our free analyst growth expectation chart.
  3. Other High Quality Alternatives: Do you like a good all-rounder? Explore our interactive list of high quality stocks to get an idea of what else is out there you may be missing!

PS. Simply Wall St updates its DCF calculation for every Finnish stock every day, so if you want to find the intrinsic value of any other stock just search here.

Valuation is complex, but we're here to simplify it.

Discover if Nexstim might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.

Access Free Analysis

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About HLSE:NXTMH

Nexstim

A medical technology company, engages in the development of non-invasive brain stimulation technologies in Finland, rest of Europe, North America, and internationally.

High growth potential with excellent balance sheet.

Advertisement